JP2008526933A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526933A5 JP2008526933A5 JP2007550826A JP2007550826A JP2008526933A5 JP 2008526933 A5 JP2008526933 A5 JP 2008526933A5 JP 2007550826 A JP2007550826 A JP 2007550826A JP 2007550826 A JP2007550826 A JP 2007550826A JP 2008526933 A5 JP2008526933 A5 JP 2008526933A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- kit
- tumor
- somatostatin
- somatostatin analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- 238000009472 formulation Methods 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 5
- 102000018997 Growth Hormone Human genes 0.000 claims 4
- 108010051696 Growth Hormone Proteins 0.000 claims 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 4
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 claims 4
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 150000001982 diacylglycerols Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000122 growth hormone Substances 0.000 claims 4
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 238000010254 subcutaneous injection Methods 0.000 claims 4
- 239000007929 subcutaneous injection Substances 0.000 claims 4
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 3
- 108010016076 Octreotide Proteins 0.000 claims 3
- 229960002700 octreotide Drugs 0.000 claims 3
- 206010000599 Acromegaly Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 206010018404 Glucagonoma Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108050001286 Somatostatin Receptor Proteins 0.000 claims 2
- 102000011096 Somatostatin receptor Human genes 0.000 claims 2
- 206010046996 Varicose vein Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000002458 carcinoid tumor Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000000052 gastrinoma Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 206010022498 insulinoma Diseases 0.000 claims 2
- 238000010255 intramuscular injection Methods 0.000 claims 2
- 239000007927 intramuscular injection Substances 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000000955 neuroendocrine Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 208000027185 varicose disease Diseases 0.000 claims 2
- SWXOGPJRIDTIRL-DOUNNPEJSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s)-1-amino-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-DOUNNPEJSA-N 0.000 claims 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 108010021336 lanreotide Proteins 0.000 claims 1
- 229960002437 lanreotide Drugs 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229940075620 somatostatin analogue Drugs 0.000 claims 1
- 229960002730 vapreotide Drugs 0.000 claims 1
- 108700029852 vapreotide Proteins 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0500807.3 | 2005-01-14 | ||
| GB0500807A GB0500807D0 (en) | 2005-01-14 | 2005-01-14 | Formulation |
| GB0507811A GB0507811D0 (en) | 2005-04-18 | 2005-04-18 | Formulation |
| GB0507811.8 | 2005-04-18 | ||
| GBPCT/GB2005/002217 | 2005-06-06 | ||
| PCT/GB2005/002217 WO2005117830A1 (en) | 2004-06-04 | 2005-06-06 | Liquid depot formulations |
| GB0518878.4 | 2005-09-15 | ||
| GB0518878A GB0518878D0 (en) | 2005-09-15 | 2005-09-15 | Formulations |
| PCT/GB2005/004748 WO2006075124A1 (en) | 2005-01-14 | 2005-12-09 | Somatostatin analogue formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526933A JP2008526933A (ja) | 2008-07-24 |
| JP2008526933A5 true JP2008526933A5 (enExample) | 2009-02-05 |
| JP5171262B2 JP5171262B2 (ja) | 2013-03-27 |
Family
ID=35986077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550826A Expired - Lifetime JP5171262B2 (ja) | 2005-01-14 | 2005-12-09 | ソマトスタチン類似体製剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1843746B1 (enExample) |
| JP (1) | JP5171262B2 (enExample) |
| KR (1) | KR100983746B1 (enExample) |
| AU (1) | AU2005324794C1 (enExample) |
| CA (1) | CA2594711C (enExample) |
| PL (1) | PL1843746T3 (enExample) |
| WO (1) | WO2006075124A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
| US8920782B2 (en) | 2005-01-14 | 2014-12-30 | Camurus Ab | Topical bioadhesive formulations |
| DE602005026998D1 (de) | 2005-01-14 | 2011-04-28 | Camurus Ab | Somatostatin-analog-formulierungen |
| CA2595385C (en) | 2005-01-21 | 2011-01-25 | Camurus Ab | Pharmaceutical lipid compositions |
| CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
| AU2015227534B2 (en) * | 2007-06-15 | 2017-02-23 | Camurus Ab | Peptide slow-release formulations |
| GB0711656D0 (en) | 2007-06-15 | 2007-07-25 | Camurus Ab | Formulations |
| AU2012202338B2 (en) * | 2007-06-15 | 2015-07-09 | Camurus Ab | Peptide slow-release formulations |
| GB0716385D0 (en) | 2007-08-22 | 2007-10-03 | Camurus Ab | Formulations |
| EP2886105B1 (en) * | 2007-10-24 | 2018-12-05 | Camurus Ab | Controlled-release formulations |
| KR100998175B1 (ko) | 2008-05-30 | 2010-12-03 | 애니젠 주식회사 | 소마토스타틴의 제조방법 |
| GB0815435D0 (en) | 2008-08-22 | 2008-10-01 | Camurus Ab | Formulations |
| WO2010105685A1 (en) * | 2009-03-19 | 2010-09-23 | Universite Pierre Et Marie Curie | Peptides for inhibiting igf-1 |
| EP2714004B1 (en) | 2011-05-25 | 2024-05-15 | Camurus AB | Controlled release peptide formulations |
| KR101494594B1 (ko) * | 2011-08-30 | 2015-02-23 | 주식회사 종근당 | 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| DK2787974T3 (en) * | 2011-12-05 | 2017-07-17 | Camurus Ab | Robust PEPTID FORMULATIONS WITH CONTROLLED RELEASE |
| TW201336526A (zh) * | 2012-01-31 | 2013-09-16 | 參天製藥股份有限公司 | 非水性液體組成物 |
| IN2014DN09831A (enExample) * | 2012-05-25 | 2015-08-07 | Camurus Ab | |
| KR101586791B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101586790B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| KR101586789B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| CN109789214B (zh) | 2016-09-27 | 2022-06-28 | 卡姆拉斯公司 | 包含edta烷基铵盐的混合物和制剂 |
| EP3421485A1 (en) | 2017-06-30 | 2019-01-02 | Université de Strasbourg | Peptides for treatment and prevention of hyperglycaemia |
| EP3437651A1 (en) | 2017-08-03 | 2019-02-06 | Université de Strasbourg | Peptides for treatment and prevention of nonalcoholic fatty liver disease |
| CN111432829B (zh) | 2017-12-14 | 2023-07-14 | 斯特拉斯堡大学 | 用于治疗和预防非酒精性脂肪肝病和纤维化的肽 |
| MX2021007460A (es) | 2018-12-21 | 2022-11-15 | Univ Strasbourg | Peptidos para el tratamiento y prevencion de diabetes y trastornos asociados. |
| JP2021059680A (ja) * | 2019-10-08 | 2021-04-15 | 花王株式会社 | 液晶組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006921A1 (en) * | 1991-10-04 | 1993-04-15 | Gs Biochem Ab | Particles, method of preparing said particles and uses thereof |
| CA2120359C (en) * | 1991-10-04 | 2000-12-26 | Tomas Landh | Particles, method of preparing said particles and uses thereof |
| SE518578C2 (sv) * | 1994-06-15 | 2002-10-29 | Gs Dev Ab | Lipidbaserad komposition |
| EP0871489A1 (en) * | 1995-10-12 | 1998-10-21 | Gs Development Ab | A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface |
| AU6919598A (en) * | 1997-04-17 | 1998-11-13 | Dumex-Alpharma A/S | A novel bioadhesive drug delivery system based on liquid crystals |
| BE1011899A6 (fr) * | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| PL1682091T3 (pl) * | 2003-11-07 | 2017-09-29 | Camurus Ab | Kompozycje lipidów i kationowych peptydów |
| CA2554052C (en) * | 2004-01-23 | 2013-10-22 | Camurus Ab | Ternary non-lamellar lipid compositions of structure forming amphiphile, structure swelling amphiphile and dispersion stabilising amphiphile |
-
2005
- 2005-12-09 WO PCT/GB2005/004748 patent/WO2006075124A1/en not_active Ceased
- 2005-12-09 PL PL05818366T patent/PL1843746T3/pl unknown
- 2005-12-09 EP EP05818366A patent/EP1843746B1/en not_active Expired - Lifetime
- 2005-12-09 CA CA2594711A patent/CA2594711C/en not_active Expired - Lifetime
- 2005-12-09 JP JP2007550826A patent/JP5171262B2/ja not_active Expired - Lifetime
- 2005-12-09 KR KR1020077018617A patent/KR100983746B1/ko not_active Expired - Lifetime
- 2005-12-09 AU AU2005324794A patent/AU2005324794C1/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526933A5 (enExample) | ||
| CA2594711A1 (en) | Somatostatin analogue formulations | |
| Strosberg et al. | Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors | |
| Susini et al. | Rationale for the use of somatostatin analogs as antitumor agents | |
| TWI624271B (zh) | 包含低黏度混合物之預調配物及其形成方法，及該低黏度混合物或預調配物之用途 | |
| HRP20161500T1 (hr) | Formulacije cikličkog somatostatina s polaganim otpuštanjem | |
| Giustina et al. | Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors | |
| Paragliola et al. | Novel somatostatin receptor ligands therapies for acromegaly | |
| Massironi et al. | Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules | |
| US9149510B2 (en) | Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes | |
| JP2019520934A (ja) | 薬剤送達デバイス | |
| Fattah et al. | Progress in the formulation and delivery of somatostatin analogs for acromegaly | |
| Calnan et al. | Potency and stability of C terminal truncated human epidermal growth factor | |
| Lauricella et al. | The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives | |
| ES2834318T3 (es) | Formulaciones de agonistas de receptores de la somatostatina | |
| Beglinger et al. | Somatostatin and octreotide: physiological background and pharmacological application. | |
| Tarasco et al. | Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats | |
| Roelfsema et al. | Therapeutic options in the management of acromegaly: focus on lanreotide Autogel® | |
| Öberg | Somatostatin analog octreotide LAR® in gastro–entero–pancreatic tumors | |
| Kyriakakis et al. | Lanreotide autogel in acromegaly–a decade on | |
| Paragliola et al. | Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors | |
| Al-Toubah et al. | Somatostatin analogs and interferon in the treatment of neuroendocrine tumors | |
| Gallmann et al. | Effect of CCK-8 on insulin-induced hyperphagia and hypothalamic orexigenic neuropeptide expression in the rat | |
| Rubio et al. | Cortistatin as a therapeutic target in inflammation | |
| Petersenn | Efficacy and limits of somatostatin analogs |